STAT Plus: Immunotherapies targeting melanoma post encouraging results, new data show
ANNE WESTON/FRANCIS CRICK INSTITUTE/WELLCOME
Iovance Biotherapeutics and Nektar Therapeutics presented updates on their melanoma programs at the Society for Immunotherapy of Cancer annual meeting.
No hay comentarios:
Publicar un comentario